Asia Pacific Anti-hypertensive Drugs Market Size & Outlook
The anti-hypertensive drugs market in Asia Pacific is expected to reach a projected revenue of US$ 9,442.2 million by 2030. A compound annual growth rate of 4.7% is expected of Asia Pacific anti-hypertensive drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$6,841.7
Forecast, 2030 (US$M)
$9,442.2
CAGR, 2024 - 2030
4.7%
Report Coverage
Asia Pacific
Asia Pacific anti-hypertensive drugs market, 2018-2030 (US$M)
Related Markets
Asia Pacific anti-hypertensive drugs market highlights
- The Asia Pacific anti-hypertensive drugs market generated a revenue of USD 6,841.7 million in 2023.
- The market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
- In terms of segment, primary hypertension was the largest revenue generating type in 2023.
- Secondary Hypertension is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 6,841.7 million |
| Market revenue in 2030 | USD 9,442.2 million |
| Growth rate | 4.7% (CAGR from 2023 to 2030) |
| Largest segment | Primary hypertension |
| Fastest growing segment | Secondary Hypertension |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Primary Hypertension, Secondary Hypertension |
| Key market players worldwide | Sanofi SA, Boehringer Ingelheim Pharma, Novartis AG ADR, Johnson & Johnson, Daiichi Sankyo Co Ltd, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, Lupin, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 29.0% of the global anti-hypertensive drugs market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 9,442.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-hypertensive Drugs Market Scope
Anti-hypertensive drugs market segmentation & scope
Anti-hypertensive Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific anti-hypertensive drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-hypertensive drugs market will help companies and investors design strategic landscapes.
Primary hypertension was the largest segment with a revenue share of 71.01% in 2023. Horizon Databook has segmented the Asia Pacific anti-hypertensive drugs market based on primary hypertension, secondary hypertension covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Anti-hypertensive Drugs Type Outlook (Revenue, USD Million, 2018-2030)
- Primary Hypertension
- Secondary Hypertension
- Asia Pacific Anti-hypertensive Drugs Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Diuretics
- ACE Inhibitors
- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Vasodilators
- Others Drug Classes
- Asia Pacific Anti-hypertensive Drugs Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Oral
- Injectables
- Other Route of Administration
- Asia Pacific Anti-hypertensive Drugs Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Reasons to subscribe to Asia Pacific anti-hypertensive drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific anti-hypertensive drugs market databook
-
Our clientele includes a mix of anti-hypertensive drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific anti-hypertensive drugs market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific anti-hypertensive drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific anti hypertensive drugs market report size, by country, 2018-2030 (US$M)
Asia Pacific Anti-hypertensive Drugs Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
